Eric Jonasch, MD, discusses the potential of HIF-2α inhibitors, an emerging class of agents for the treatment of patients with renal cell carcinoma. Jonasch is a professor in the Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center.
Vobramitamab duocarmazine continues to show promise in mCRPC
May 10th 2024Updated data from the phase 2 TAMARCK study continued to show safety and preliminary efficacy with the B7-H3–targeting antibody-drug conjugate vobramitamab duocarmazine in patients with metastatic castration-resistant prostate cancer.